Even as the Trump administration looks for ways to mollify angry consumers over rising drug prices, some companies continue to push the proverbial envelope.
Take Bayer.
Late last month, the drug maker boosted wholesale, or list, prices for two cancer drugs by 7.9 percent. And that followed 5 percent price hikes last December. In other words, prices rose by 13 percent for each drug in half a year, greatly exceeding inflation and above the 10 percent annual cap that some drug makers have voluntarily embraced.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
